Rosiglitazone negatively regulates c-Jun N-terminal kinase and toll-like receptor 4 proinflammatory signalling during initiation of experimental aortic aneurysms

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 69-75

  Pirianov, Grisha ^a   Torsney, Evelyn ^a   Howe, Franklyn ^a   Cockerill, Gillian W ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Aneurysm; Angiotensin II; C Jun N terminal kinase; Inflammation; Thiazolidinediones; Toll like receptor 4

Indexed keywords

ANGIOTENSIN II; ANTIBODY; APOLIPOPROTEIN E; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ANEURYSM; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM; AORTIC RUPTURE; DOWN-REGULATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TOLL-LIKE RECEPTOR 4;

EID: 84867873369     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.07.034     Document Type: Article

References (32)

1. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998, 352:1649-1655. The UK small aneurysm trial participants.
2. Zack M., Boyanovsky B.B., Shridas P., et al. Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis 2011, 214:58-64.
3. Wills A., Thompson M.M., Crowther M., Sayers R.D., Bell P.R. Pathogenesis of abdominal aortic aneurysms-cellular and biochemical mechanisms. Eur J Vasc Endovasc Surg 1996, 12:391-400.
4. Sho E., Sho M., Nanjo H., Kawamura K., Masuda H., Dalman R.L. Hemodynamic regulation of CD34+ cell localisation and differentiation in experimental aneurysms. Arterioscler Thromb Vasc Biol 2004, 24:1916-1921.
5. Tang P.C., Coady M.A., Lovoulos L., et al. Hyperplastic cellular remodelling if the media in ascending thoracic aortic aneurysms. Circulation 2005, 112:1098-1105.
6. Sinha I., Sinha-Hakim A.P., Hannawa K.K., et al. Mitochondrial-dependant apoptosis in experimental rodent abdominal aortic aneurysms. Surgery 2005, 138:806-811.
7. Choke E., Dawson J., Wilson W.R., Loftus I.M., Thompson M.M., Cockerill G.W. Upregulation of pro-angiogenic mediators and increased angiogenesis at the site of abdominal aortic aneurysm rupture. Arterioscler Thromb Vasc Biol 2006, 1085:315-319.
8. Jones A., Deb R., Torsney E., et al. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation 2009, 119:3125-3132.
9. Marx N., Duez H., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004, 94:1168-1178.
10. Keen H.L., Ryan M.J., Beyer A., et al. Gene expression profiling of potential PPARgamma target genes in mouse aorta. Physiol Genomics 2004, 18:33-42.
11. Yoshimura K., Aoki H., Ikeda Y., Furutani A., Hamano K., Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase in mice. Ann N Y Acad Sci 2006, 1085:74-81.
12. Yoshimura K., Aoki H., Ikeda Y., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005, 11:1330-1338.
13. Laaksamo E., Tulamo R., Baumann M., et al. Involvement of mitogen-activated protein kinase signaling in growth and rupture of human intracranial aneurysms. Stroke 2008, 39:886-892.
14. Owens A.P., Rateri D.L., Howatt D.A., et al. MyD88 deficiency attenuates angiotensin II-Induced abdominal aortic aneurysm formation independent of signaling through toll-like receptors 2 and 4. Arterioscler Thromb Vasc Biol 2011, 12:2813-2819.
15. Song J.S., Kim C.H., Heo J.Y., Cho Y.S. Rosiglitazone reduces a wide range of proinflammatory profiles in synovial fibroblast SW982 under spheroid culture. Immunol Lett 2010, 131:81-88.
16. Khandouni N., Delerive P., Berrebi-Bertand I., Buckinham R.E., Stels B., Bril A. Rosiglitazone, a peroxisome proliferators-activated receptor-G, inhibits the Jun NH2-terminal kinase.activated protein I pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002, 51:1507-1514.
17. Morrison A., Yan X., Tong C., Li J. Acute Rosiglitazone treatment is cardioprotective against ischemia/reperfusion injury by modulating AMPK, Akt, and JNK signaling in non-diabetic mice. Am J Physiol Heart Circ Physiol 2011, 301:895-903.
18. Weber S.M., Scarim A.L., Corbett J.A. PPARgamma is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic beta-cells. Am J Physiol Endocrinol Metab 2004, 286:E329-E336.
19. Pirianov G., Waddington S.N., Lindström T.M., Terzidou V., Mehmet H., Bennett P.R. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J(2) delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse. Endocrinology 2009, 15:699-706.
20. Zakkar M., Chaudhury H., Sandvik G., et al. Increased endothelial mitogen-activated protein kinase phosphatase-1 expression suppresses proinflammatory activation at sites that are resistant to atherosclerosis. Circ Res 2008, 103:726-732.
21. Shepherd R.D., Kos S.M., Rinker K.D. Long term shear stress leads to increased phosphorylation of multiple MAPK species in cultured human aortic endothelial cells. Biorheology 2009, 46:529-538.
22. Shyu K.G., Wang B.W., Lin C.M., Chang H. Cyclic stretch enhances the expression of toll-like receptor 4 gene in cultured cardiomyocytes via p38 MAP kinase and NF-kappaB pathway. J Biomed Sci 2010, 5:13-15.
23. Bondeva T., Roger T., Wolf G. Differential regulation of toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites. Am J Nephrol 2007, 27:308-314.
24. Tachibana H., Perrino C., Takaoka H., Davis R.J., Naga Prasad S.V., Rockman H.A. JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem Biophys Res Commun 2006, 343:1060-1066.
25. Zhou M.S., Schulman I.H., Chadipiralla K., Raij L. Role of c-Jun N-terminal kinase in the regulation of vascular tone. Cardiovasc Pharmacol Ther 2010, 15:78-83.
26. Osto E., Matter C.M., Kouroedov A., et al. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation 2008, 118:2073-2080.
27. Pirianov G., Jesurasa A., Mehmet H. Developmentally regulated changes in c-Jun N-terminal kinase signalling determine the apoptotic response of oligodendrocyte lineage cells. Cell Death Differ 2006, 13:531-533.
28. Daugherty A., Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 2004, 14:117-120.
29. Ji Y., Liu J., Wang Z., Liu N., Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependant signaling pathway. Lab Invest 2009, 89(8):887-902.
30. Zhai D., Zhang J., Zheng Q., Li Z., Zhang J., Tian Y. Significance of rosiglitazone inhibiting TLR4 expression in partial hepatic ischemia/reperfusion of mice. J Huazhong Univ Sci Techno Med Sci 2008, 28:564-567.
31. Yamanouchi D., Morgan S., Kato K., Lengfeld J., Zhang F., Liu B. Effects of caspase inhibitor on angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011, 30:702-707.
32. Tikellis C., Jandeleit-Dahm K., Sheehy K., et al. Reduced plaque formation inducede by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis 2008, 199:55-64.